Would like to see the details that come out of the Investor Briefing, before judging too much. From the Appendix4C it looks like a fairly big jump on the last quarter for administration and corporate costs, and a fairly insignificant sum spent on marketing. Understand they have self marketed a bit through news interviews etc and have been selling b2b but $9000..... seems quite paltry when they are selling HIV tests direct to the public. A more positive view would be they are saving using partner organisations to move product but a breakdown of where sales are coming from would be nice.
These are my views/opinions only please do your own research
AT1 Price at posting:
22.0¢ Sentiment: None Disclosure: Held
